APA (7th ed.) Citation

Chinen, Y., Tanba, K., Takagi, R., Uchiyama, H., Uoshima, N., Shimura, K., . . . Kuroda, J. (2020). Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. Leukemia & Lymphoma, 61(14), 3378. https://doi.org/10.1080/10428194.2020.1811862

Chicago Style (17th ed.) Citation

Chinen, Yoshiaki, et al. "Second Primary Malignancy After Rituximab-containing Immunochemotherapy for Diffuse Large B Cell Lymphoma." Leukemia & Lymphoma 61, no. 14 (2020): 3378. https://doi.org/10.1080/10428194.2020.1811862.

MLA (9th ed.) Citation

Chinen, Yoshiaki, et al. "Second Primary Malignancy After Rituximab-containing Immunochemotherapy for Diffuse Large B Cell Lymphoma." Leukemia & Lymphoma, vol. 61, no. 14, 2020, p. 3378, https://doi.org/10.1080/10428194.2020.1811862.